Negative phase 3 study of 90Y microspheres versus sorafenib in HCC - Université de Rennes Access content directly
Journal Articles Lancet Oncology Year : 2018

Dates and versions

hal-01718024 , version 1 (27-02-2018)

Identifiers

Cite

Etienne Garin, Yan Rolland, Boris Campillo-Gimenez, Julien Edeline. Negative phase 3 study of 90Y microspheres versus sorafenib in HCC. Lancet Oncology, 2018, 19 (2), pp.e70. ⟨10.1016/S1470-2045(18)30024-X⟩. ⟨hal-01718024⟩
42 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More